| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785742 | Cancer Treatment and Research Communications | 2018 | 5 Pages |
Abstract
Our preliminary results show that iXip identifies a sub-group of patients who can safely avoid rebiopsy because they do not have PCa. The index is a promising tool that could reduce the number of unnecessary prostate biopsies and the relative clinical complications and expenses.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrea Benedetto Galosi, Lucio Dell'Atti, Alessandro Bertaccini, Massimo Gion, Simone Francavilla, Stefania Ferretti, Umberto Maestroni, Andrea Gallotta, Chiara Parrozzani, Laura Paneghetti, Giorgio Fassina,